BioSpace News Archive

Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that Andrew Miller, Ph.D., founder and chief operating officer at Karuna, will present and host investor meetings at the Piper Jaffray 31st Annual Healthcare Conference

Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that it has elected Frank S. Friedman to its Board of Directors

Delta-Fly Pharma, Inc. (TOKYO: 4598) announces that patients have registered for clinical studies in the USA on anti-cancer drug candidates DFP-10917 and DFP-14927

Iron Deficiency Day is an international event which raises awareness of the serious impact of iron deficiency and iron deficiency anaemia

US Medical Innovations, LLC (USMI), a Biomedical and Life Science subsidiary of US Patent Innovations, LLC (USPI) announced today the U.S. Food And Drug Administration (FDA) 510(k) clearance (#K192124) to market and sell the Canady Plasma® Smart XL-1000™ Electrosurgical Generator (CPSXEG) with accessories.

Renovia Inc. (“Renovia”), a company dedicated to discovering and delivering first-line digital therapeutic and diagnostic device and app technologies for women with pelvic floor disorders, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the next-generation leva® Pelvic Digital Therapeutic for the strengthening of pelvic floor muscles and the treatment of stress, mixed and mild to moderate urgency urinary incontinence (UI) in women.

PharmaCyte Biotech, Inc. (OTCQB: PMCB), announced today an update on the completed tests that are part of the U.S. Food and Drug Administration (FDA) required “release testing” related to the company’s first manufactured batch of its clinical trial product to be used in its planned Phase 2b clinical trial in locally advanced, inoperable pancreatic cancer (LAPC).

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that company management will participate at the Evercore ISI 2nd Annual HealthCONx Conference

Clinical evidence demonstrating the effectiveness of new FDA-cleared assays for the detection of vaginitis has been published online in the Journal of Clinical Microbiology.

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the initiation of its Phase 1 clinical trial of Voriconazole Inhalation Powder